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The coronavirus disease 2019 (Covid-19) pandemic is precipitating the global health crisis 
of our time, as stated by the World Health Organization (WHO). Since it surge in December 2019, 
in Wuhan, Hubei province, China, the virus has spread to every continent except Antarctica. The 
main clinical manifestation of SARS-CoV-2 is severe acute respiratory syndrome which yields to 
inflammatory reaction and alveolar fluid floading ultimately impairing gas exchange. 1-3   
 Reports have clearly established that hypertension, diabetes, and cardiovascular diseases 
are the most frequent comorbidities in affected patients, and these individuals are exposed to the 
highest mortality rates. 4, 5  
Most of these patients suffer from already preexistent or rapidly evolving heart failure (HF) 
6, 7 and they are commonly treated with renin angiotensin system blockers, such as angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) as Guidelines Class I, 
Level of Evidence A. 8 However, there is an ongoing debate about  the use of ACEIs/ARBs in 
patients with Covid-19 or at risk of SARS-CoV-2 infection which may not be beneficial or even 
harmful. 9 Vaduganathan et al 10 have recently reported an elegant and comprehensive revision on 
the controversial aspects of this topic providing the most updated evidence.  
We gained previous experience on the effects of renin-angiotensin system inhibition on the 
pulmonary function of HF patients showing a protective effect on the perturbed gas exchange and 
lung fluid handling, i.e. alveolar capillary stress-failure, an effect especially observed with enalapril 
treatment, with a positive but statistically not signfiicnat trend for losartan 11, 12 .  
Based on this, we outline how renin angiotensin blockers may interact with the lung fluid 
handling and gas diffusion process in patients with HF infected by SARS-CoV-2, and propose areas 
for further research. 
Both ACE and ACE2 are homologous enzymes part of the ACE family of the dipeptidyl and 
monopeptidyl carboxydipeptidases, respectively, with different key functions in the renin 
angiotensin system. ACE cleaves angiotensin (Ang) I to angiotensin (Ang) II, which in turn binds 
and activates Ang II receptors type 1 and type 2. Activation of type 1 receptors leads to 
vasoconstrictive, proinflammatory, and pro-oxidative effects. ACE2 cleaves Ang I to Ang-(1-9) and 
to Ang-(1-7). ACE2 also mediates the conversion of Ang II to Ang-(1-7) which binds to the Mas 
receptor and promotes anti-inflammatory, antioxidative, and vasodilatory effects. 13  
All these effects are well studied and documented for the systemic circulation, but 
information regarding their activity on the pulmonary microcirculation are mostly lacking. 
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Interestingly, ACE is produced in the lung tissue and released by the pulmonary circulation. In 
humans, ACE2 is predominantly expressed in the alveolar Type II cells and enterocytes of the small 
intestine. 14   
SARS-CoV-2 utilizes lung ACE2 as an essential receptor for cell entry and host cellular 
proteases into the alveolar Type II cells. Namely, the spike (S) protein of SARS-CoV-2 is primed by a 
transmembrane cellular serine protease, TMPRSS2 2, which allows fusion of viral and cellular 
membranes. 15  
Physiologically, fluid handling across the alveolar gas barrier is modulated by cellular and 
molecular mechanisms of ions and fluid transposition as depicted in the Figure.  The alveolar 
surface is continuously cleared by the excess of fluid through the activity of energy-independent 
epithelial sodium channels (eNaC) and acquaporins. 16 Fluid is then transposed by ATP Na+/K+ 
pumps into the vascular compartment. These protective pathways, which are essential to keep the 
alveolar surface dry and guarantee gas exchange, are highly challenged by a number of 
hemodynamic, inflammatory and growth factor stimuli typical of HF syndrome. 3, 17 Interstitial 
fibrosis and capillary remodeling ensue when the fluid triggers the inflammatory cascade and 
connective tissue reaction. 18 In HF with pulmonary congestion and inflammation and even some 
reactive interstitial fibrosis, renin angiotensin system blockade by ACEI has been shown to 
promote a protective effect on lung fluid swelling from capillaries to interstitium and “speed-up” 
the fluid clearance during saline loading with improved gas exchange. 11, 12, 19 
The infection by SARS-CoV-2 specifically challenges and disrupts the fine protective 
mechanisms of ion regulatory transport and precipitate the edematous-inflammatory cascade.20  
Renin angiotensin system blockade increases the ACE2 overexpression and in SARS-CoV-2 
free conditions there is a strong rationale that ACE2 may mediate these beneficial effects. 21, 22 
Thus, in conditions of SARS-CoV-2 infection the ACE2 activity appears downregulated 
yielding to an unfavorable Ang II/Ang-(1-7) balance. 23 Of note, Ang-(1-7) plays a crucial protective 
role against lung inflammation. Specifically, this heptapeptide inhibits alveolar apoptosis, limits 
the synthesis of cytokines and attenuates endothelial cell activation and the loss of barrier 
function and oedema. 24  
Experimental models of genetically-modified mice undergoing acute lung injury have 
documented an ACE2 protein downregulation by binding its spike protein and this loss leads to a 
leaky capillary effect through stimulation of AT1 receptors. 25 Interestingly enough, the ACE2 
knockout strain exhibited the worse edematous and inflammatory response and pretreatment 
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with exogenous recombinant human ACE2 attenuated acute lung failure in ACE2 knockout as well 
as in the wild-type mice. 25   
Additional experimental observations looking at hyperoxia treatment showed significant 
reduction in lung ACE2 expression/activity and increased Ang II/Ang-(1-7) ratio in adult mice 
exposed to 95% O2 for 72 h. It has also been demonstrated that activation of ACE2 can reduce the 
severity of hyperoxic lung injury by inhibiting inflammatory response and oxidative stress and that 
ACE2 can inhibit the NF-κB and activate the Nrf2/HO-1/NQO1 pathways, which may be involved in 
the underlying mechanism. 26  A pre Covid-19 trial of ACE2 infusion in 10 patients with acute 
respiratory distress syndrome was completed in humans but was not powered to show efficacy on 
gas exchange. 27 
A main question, however, is whether the SARS-CoV-2 ability to neutralize ACE2 activity 
could be so powerful to neutralize the additive protection of ACE2 overexpression, definitively 
leading to an untoward negative cascade of lung fluid compartimentalization, 
ventilation/perfusion mismatch and impaired gas exchange.  
This key issue will be likely clarified soon but, meanwhile, reasoning on this double edge 
front, it is tempting to speculate that ARBs could divert a larger amount of angiotensin II to the 
ACE2 activity, even though it remains unpredictable what level of benefit or harm could be 
observed with ARBs versus ACEIs. 
In the rapidly evolving scenario of pandemia, the present observations could enhance our 
understanding on how treatment with renin angiotensin system blockers may impact Covid-19 HF 
patients.  
Accordingly, we highly advocate that upcoming basic science and clinical proof of concept 
studies should scrutinize the aforementioned working hypotheses and theories.  
On one hand, preclinical studies should be planned for definitively establishing the 
interaction between molecular pathways involved in the alveolar-capillary fluid handling and ACE2 
activity in knockout ACE2 -/- versus ACE2 +/+ animal models of SAR-CoV-2 lung injury. 
On the other hand, clinical studies should recruit SARS-CoV-2 asymptomatic carriers to test 
how the inhibition of renin angiotensin system, by randomization to ACE-I or ARB, could impact on 
the fluid homeostasis and gas exchange processes by mitigating or worsening their fundamental 
physiology, peculiarly threatened by the SARS-CoV-2 infection. 
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Figure Legend- Schematic representation of fluid handling trough the alveolar-capillary barrier 
and potential effects of RAS-system inhibition and ACE2 levels in the normal and Covid-19 
condition 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
  
Fluid is continuously removed from the alveoli (type II pneumocytes) to the interstitium by 
the epithelial Na+ channels (eNaC) and acquaporins. Then removal of fluid from the intertistium to 
the vascular compartment is driven by osmosis and Na+/K+ ATPase pump. These mechanisms are 
essential for guarantee an efficient gas exchange. Multiple conditions, and primarily HF, challenge 
the integrity of the alveolar-capillary unit and the functional response of these molecular 
mechanisms. The best in vivo method to assess how these systems work is measuring gas 
exchange. 
Studies performed in HF patients under treatment with renin angiotensin system blockade, 
especially ACEI, investigating the gas exchange response under fluid loading have shown a 
facilitating effect on the on alveolar capillary membrane gas diffusion. This effect would be 
mediated by high ACE2-induced Ang-(1-7) production and low Angio II. 
SARS-CoV-2 binds to ACE2 for entering and injury the type II cells leading to an 
inflammatory reaction and cytokines release. ACE2 expression activity is down-regulated in 
experimental models of ARDS and overexpression of ACE2 in null models is beneficial.  
RAS-inhibitors (ACEIs and primarily ARBs) stimulate ACE2 synthesis and Ang II conversion to 
Ang-(1-7) which may be of benefit or even harmful according to the degree of affinity and the 
reciprocal neutralizing effects between ACE2 and SARS-CoV-2. 
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